Related Experiment Video

Updated: Aug 17, 2026

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies
09:29

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies

Published on: September 30, 2016

Emerging drugs in colorectal cancer

Lucy Scott1, Judith Fraser, Jim Cassidy

  • 1Department of Medical Oncology, Beatson Oncology Center, Western Infirmary, Dumbarton Road, Glasgow, Scotland, UK.

Expert Opinion on Emerging Drugs
|November 13, 2003
PubMed

Insights

Novel colorectal cancer treatments are emerging to challenge 5-fluorouracil (5-FU). Research is exploring oral fluoropyrimidines, topoisomerase I inhibitors, platinum compounds, and targeted biological therapies to improve patient outcomes.

Area of Science:

  • Oncology
  • Pharmacology
  • Cancer Therapeutics

Background:

  • 5-fluorouracil (5-FU) has been the standard treatment for colorectal cancer.
  • Current treatments face limitations in efficacy and toxicity.
  • There is a need for improved therapeutic strategies for colorectal cancer.

Purpose of the Study:

  • To review novel therapeutic agents for colorectal cancer.
  • To discuss emerging treatment modalities challenging the current standard of care.
  • To highlight the potential of new drugs to improve patient response rates and survival.

Main Methods:

  • Literature review of recent advancements in colorectal cancer pharmacotherapy.
  • Analysis of novel agents including oral fluoropyrimidines, topoisomerase I inhibitors, and platinum compounds.
  • Exploration of biological therapies and their potential for personalized treatment.

Main Results:

  • Several novel agents with distinct mechanisms of action are under investigation.
  • Biological therapies offer potential for tailored treatments with reduced toxicity.
  • New drug development aims to overcome limitations of conventional cytotoxic therapies.

Conclusions:

  • Emerging therapies show promise in challenging the established role of 5-FU in colorectal cancer treatment.
  • Personalized medicine approaches using biological therapies may enhance treatment efficacy and patient safety.
  • Advancements in drug development are expected to improve survival rates for colorectal cancer patients.

More Related Videos

Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer08:12

Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer

Published on: March 14, 2019

Discovery of Driver Genes in Colorectal HT29-derived Cancer Stem-Like Tumorspheres06:52

Discovery of Driver Genes in Colorectal HT29-derived Cancer Stem-Like Tumorspheres

Published on: July 22, 2020

Related Concept Videos

Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Drugs that Destabilize Microtubules01:10

Drugs that Destabilize Microtubules

Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
Drugs for Treatment of Diarrhea-Predominant IBS01:17

Drugs for Treatment of Diarrhea-Predominant IBS

Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Drugs for Treatment of Ulcerative Colitis in IBD01:29

Drugs for Treatment of Ulcerative Colitis in IBD

Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide generation. 
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...